Nuvation Bio: JPMorgan Sees Strong Ibtrozi Launch and Pipeline Upside

JPMorgan initiates Nuvation Bio at Overweight with $13 target, citing durable first-line adoption of Ibtrozi in ROS1+ lung cancer.